A phase I clinical study carried out in 24 advanced stage NPC patients demonstrated the safety and immunogenicity of a recombinant type 5 adenovirus (Ad5) (one of the least pathogenic for humans) expressing LMP2 protein (Borovjagin et al., 2014). This evidence concerns the gene PSMB9 and nasopharyngeal carcinoma.